| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-169 |
Sentence |
denotes |
Twelve weeks' treatment with a polyphenol-rich seaweed extract increased HDL cholesterol with no change in other biomarkers of chronic disease risk in overweight adults: |
| T2 |
170-208 |
Sentence |
denotes |
A placebo-controlled randomized trial. |
| T3 |
209-277 |
Sentence |
denotes |
Cardiovascular diseases (CVD) are the leading global cause of death. |
| T4 |
278-328 |
Sentence |
denotes |
Strategies to reduce CVD risk are urgently needed. |
| T5 |
329-498 |
Sentence |
denotes |
Polyphenols represent a class of bioactive compounds with potential to moderate biochemical risk factors for CVD (cholesterol, triglycerides, glucose, and inflammation). |
| T6 |
499-687 |
Sentence |
denotes |
This double-blind, placebo-controlled, randomized parallel-groups trial investigated the effect of a polyphenol-rich seaweed (Fucus vesiculosus) extract on biochemical markers of CVD risk. |
| T7 |
688-899 |
Sentence |
denotes |
Thirty-four overweight and obese adults (21 female, 13 male) with elevated low-density lipoprotein cholesterol (>2.0 mmol/L) were randomized to either the seaweed extract (2000 mg/d) or placebo for twelve weeks. |
| T8 |
900-1005 |
Sentence |
denotes |
Fasting blood samples were collected at baseline, week six and week twelve to assess biochemical markers. |
| T9 |
1006-1099 |
Sentence |
denotes |
Tests of cognitive performance and mood were performed at baseline, week six and week twelve. |
| T10 |
1100-1269 |
Sentence |
denotes |
A 9.5% (-2.3, 12.9) increase in high-density lipoprotein (HDL) cholesterol was identified following the seaweed extract (baseline: mean (SD) 1.28 (0.23) mmol/L, week 12: |
| T11 |
1270-1331 |
Sentence |
denotes |
1.35 (0.24) mmol/L) which was different to placebo (baseline: |
| T12 |
1332-1360 |
Sentence |
denotes |
1.38 (0.54) mmol/L, week 12: |
| T13 |
1361-1390 |
Sentence |
denotes |
1.35 (0.59) mmol/L) (P=.045). |
| T14 |
1391-1679 |
Sentence |
denotes |
No changes were identified in low-density lipoprotein cholesterol, total cholesterol, triglycerides, glucose, insulin, interleukin (IL)-2, IL-6, IL-8, IL-10, or tumour necrosis factor-alpha levels in the blood, or in cognitive performance or mood between the treatment and placebo groups. |
| T15 |
1680-1839 |
Sentence |
denotes |
Despite the small increase observed in HDL cholesterol, the polyphenol-rich seaweed extract did not change CVD risk factors in adults with high fasting lipids. |
| T16 |
1840-1947 |
Sentence |
denotes |
A larger sample size would be required to confirm the clinical relevance of the changes in HDL cholesterol. |
| T1 |
0-169 |
Sentence |
denotes |
Twelve weeks' treatment with a polyphenol-rich seaweed extract increased HDL cholesterol with no change in other biomarkers of chronic disease risk in overweight adults: |
| T2 |
170-208 |
Sentence |
denotes |
A placebo-controlled randomized trial. |
| T3 |
209-277 |
Sentence |
denotes |
Cardiovascular diseases (CVD) are the leading global cause of death. |
| T4 |
278-328 |
Sentence |
denotes |
Strategies to reduce CVD risk are urgently needed. |
| T5 |
329-498 |
Sentence |
denotes |
Polyphenols represent a class of bioactive compounds with potential to moderate biochemical risk factors for CVD (cholesterol, triglycerides, glucose, and inflammation). |
| T6 |
499-687 |
Sentence |
denotes |
This double-blind, placebo-controlled, randomized parallel-groups trial investigated the effect of a polyphenol-rich seaweed (Fucus vesiculosus) extract on biochemical markers of CVD risk. |
| T7 |
688-899 |
Sentence |
denotes |
Thirty-four overweight and obese adults (21 female, 13 male) with elevated low-density lipoprotein cholesterol (>2.0 mmol/L) were randomized to either the seaweed extract (2000 mg/d) or placebo for twelve weeks. |
| T8 |
900-1005 |
Sentence |
denotes |
Fasting blood samples were collected at baseline, week six and week twelve to assess biochemical markers. |
| T9 |
1006-1099 |
Sentence |
denotes |
Tests of cognitive performance and mood were performed at baseline, week six and week twelve. |
| T10 |
1100-1269 |
Sentence |
denotes |
A 9.5% (-2.3, 12.9) increase in high-density lipoprotein (HDL) cholesterol was identified following the seaweed extract (baseline: mean (SD) 1.28 (0.23) mmol/L, week 12: |
| T11 |
1270-1331 |
Sentence |
denotes |
1.35 (0.24) mmol/L) which was different to placebo (baseline: |
| T12 |
1332-1360 |
Sentence |
denotes |
1.38 (0.54) mmol/L, week 12: |
| T13 |
1361-1390 |
Sentence |
denotes |
1.35 (0.59) mmol/L) (P=.045). |
| T14 |
1391-1679 |
Sentence |
denotes |
No changes were identified in low-density lipoprotein cholesterol, total cholesterol, triglycerides, glucose, insulin, interleukin (IL)-2, IL-6, IL-8, IL-10, or tumour necrosis factor-alpha levels in the blood, or in cognitive performance or mood between the treatment and placebo groups. |
| T15 |
1680-1839 |
Sentence |
denotes |
Despite the small increase observed in HDL cholesterol, the polyphenol-rich seaweed extract did not change CVD risk factors in adults with high fasting lipids. |
| T16 |
1840-1947 |
Sentence |
denotes |
A larger sample size would be required to confirm the clinical relevance of the changes in HDL cholesterol. |